The much-anticipated hearings on the proposed rulemaking to reschedule cannabis, which were scheduled to begin on January 21, have been postponed for at least three months as a result of an appeal granted by DEA...more
2/5/2025
/ Administrative Law Judge (ALJ) ,
Agribusiness ,
Appeals ,
Controlled Substances Act ,
DEA ,
Decriminalization of Marijuana ,
Department of Health and Human Services (HHS) ,
Marijuana ,
Medical Marijuana ,
Plant Based Products ,
Rulemaking Process ,
Schedule I Drugs ,
Trump Administration
With an expanding cannabis and hemp market and an upcoming legislative session that will consider medical cannabis expansion, hemp regulation, decriminalization, and other cannabis matters—we have our eyes on Texas! Texas...more
After 50 years of being on the most restrictive schedule alongside drugs like heroin and PCP, the DEA will move to reschedule marijuana in Schedule III, where the plant’s medical benefits will finally be recognized by the...more
5/1/2024
/ Agribusiness ,
Controlled Substances Act ,
Corporate Counsel ,
DEA ,
Decriminalization of Marijuana ,
Department of Justice (DOJ) ,
Financial Services Industry ,
Food and Drug Administration (FDA) ,
Marijuana ,
Marijuana Related Businesses ,
Medical Marijuana ,
Medical Research ,
Popular ,
Schedule I Drugs
On August 30, 2023, the federal government formally acknowledged the medical use and low potential of abuse for cannabis, with the US Department of Health and Human Services (HHS) recommending that cannabis be rescheduled to...more
9/1/2023
/ Biden Administration ,
Cannabis-Related Businesses (CRBs) ,
Controlled Substances Act ,
Criminal Justice Reform ,
DEA ,
Decriminalization of Marijuana ,
Department of Health and Human Services (HHS) ,
Department of Justice (DOJ) ,
Drug Treatment ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Internal Revenue Code (IRC) ,
IRS ,
Medical Marijuana ,
Medical Research ,
Pharmaceutical Industry ,
Popular ,
Schedule I Drugs ,
Tax Penalties